Regenerative Medical Technology Group Inc.

What they do

RMTG runs four connected businesses: ISSCA, its physician education and certification arm; Cellgenic, which manufactures and sells biologics such as exosomes, mesenchymal stem cells and peptides; the Cellular Institute clinical network, which delivers patient treatments and generates clinical data; and an international expansion effort including franchise and Turnkey membership arrangements. It sells to physicians, medical providers and affiliated clinics, and states its network covers 26 clinics in 21 countries with its own clinic in Cancun.

Revenue drivers

• Product supplies (Cellgenic) — Largest line at $2,024,573 in 2025 versus $1,748,961 in 2024, covering recurring sales of exosomes, stem cells, peptides and combination therapies, plus the exclusive-purchase Turnkey membership program.
• Patient procedures — Second largest at $1,874,386 in 2025 versus $1,371,654 in 2024, driven by higher patient volumes and a shift toward premium regenerative treatments at company clinical operations.
• Training and certification — $1,125,521 in 2025 versus $809,654 in 2024, generated through 15 international ISSCA events, certifications, symposiums and online programs; management signed three new affiliate partners during 2025.
• Equipment and kits — Smallest line and the only one that declined, at $75,835 in 2025 versus $177,225 in 2024, covering automated processing systems, diagnostic tools and kits sold alongside products and training.

Recent performance

Fiscal 2025 revenue rose 24.17% to $5,100,315 from $4,107,494, but cost of revenue rose 78.26% to $2,289,537, leaving gross profit essentially flat at $2,810,778 versus $2,823,119. Total operating expenses increased 34.14% to $3,677,940, producing a net loss from operations of $867,162 compared with operating income of $81,181 in 2024. Interest expense of $7,447,780 drove a 2025 net loss of $7,812,409, or $0.62 per diluted share, versus a $5,562,971 loss in 2024. Quarterly revenue has since climbed from $1.2M in the September 2025 quarter to $4.0M in the June 2026 quarter, and the 10-Q reports continued execution on 2026 priorities including the ISSCA Mobile App and ISSCA AI Clinical Intelligence Platform launched in June 2026.

Strategy

Management describes a four-pillar platform strategy: ISSCA education as the physician acquisition engine, Cellgenic manufacturing as the high-margin product engine, the clinical center network as both revenue source and validation platform, and international expansion as the repeatable scaling mechanism. Stated priorities for 2026 include launching a Diploma in Cell Therapy & Tissue Engineering, postgraduate curricula and fellowship training, and scaling Cellgenic output into next-generation exosome, peptide and combination therapies. The company is developing a standardized clinical and franchise model through Cellular Institute and reports strengthening regulatory alignment in markets such as Argentina. Two digital assets launched in June 2026, the ISSCA Mobile App and ISSCA AI Clinical Intelligence Platform, are intended to convert in-person education relationships into recurring digital revenue.

Risks

• Going concern and financing — At June 30, 2026 the company reported total liabilities of $45.1M against total assets of $5.9M and shareholder equity of negative $39.3M, with cash of $1.3M.
• Debt in default — The 10-Q risk factors cite outstanding secured and unsecured loans, certain of which are in default, and the company's ability to service that debt.
• Persistent losses — Net losses were $7.8M in 2025, $5.6M in 2024 and $9.8M in 2023, and interest expense alone was $7,447,780 in 2025.
• Regulatory exposure — The company cites legislative or regulatory changes concerning regenerative medicine and therapies, an area in which its training, biologics and patient procedure revenue all sit.

Outlook

Management calls 2026 a pivotal year of strategic execution and platform maturation, expecting to transition from a high-growth operator into a consolidated category leader in regenerative medicine. It anticipates revenue acceleration, margin expansion and improved operational efficiency from the vertically integrated model, and cites unaudited first-quarter 2026 revenue up 69% over the fourth quarter of 2025. A May 2025 earnings release said the company expected to issue official revenue guidance for the remainder of that year and the following two years in a subsequent release, and to onboard one new Turnkey member per quarter initially.